Oncolytics Biotech Shows Favorable Safety for Pelareorep in GI Tumors
SAN DIEGO, Sept. 2, 2025 – Oncolytics Biotech® Inc. (Nasdaq: ONCY), a clinical-stage immunotherapy company, announced updated clinical safety...
Clinical Trials for New Therapy
Sanofi’s Wayrilz Approved in the U.S. as First BTK Inhibitor for Immune Thrombocytopenia
Sanofi has secured U.S. FDA approval for Wayrilz (rilzabrutinib), marking the first Bruton’s tyrosine kinase (BTK) inhibitor approved for...
Veeva Systems and Amgen Collaborate to Accelerate Innovation in Clinical Trials
Veeva Systems (NYSE: VEEV) today announced a strategic collaboration with global biotechnology leader Amgen to drive innovation in clinical...
Stramsen Biotech Submits Pre-IND Package to FDA for SBX1977, Seeks Phase 2 Pathway in Wound Care
Stramsen Biotech Inc., a plant-based biotechnology company, has announced the submission of its Pre-Investigational New Drug (Pre-IND) package to...
Glycovax Pharma to Develop Pseudomonas Vaccine After NRC License Approval
MONTREAL, Aug. 18, 2025 — Glycovax Pharma has secured a license from the National Research Council of Canada (NRC)...
CorrectSequence Therapeutics Promising Results for World’s First Cure of Sickle Cell via transformer Base Editing
Shanghai, China, August 26, 2025 – In a landmark advancement, CorrectSequence Therapeutics Co., Ltd. (Correctseq) has announced the first...
Sanofi’s Rilzabrutinib Gets EU Orphan Drug Status for IgG4-Related Disease
Paris, August 14, 2025 – The European Medicines Agency (EMA) has granted orphan drug designation to Sanofi’s rilzabrutinib, a...
Private Equity Firm, THL to Acquire Clinical Trial Site Network, Headlands Research from KKR
Lake Worth, FL. & New York, August 23, 2025 – Thomas H. Lee Partners (THL) has entered into a...
First Patient Dosed in Akeso’s Phase III Trial of Cadonilimab for Resectable Gastric Cancer
Hong Kong, August 20, 2025 — Akeso, Inc. (9926.HK) has announced the enrollment and dosing of the first patient...